ScreenerHero

GNPXGenprex, Inc.

NAS · US · Healthcare · Biotechnology · genprex.com
3.950USD-1.00%Mkt Cap: 3.24M $P/E: 0.12

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.24M $
Enterprise Value-11.92M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-16.23M $
Revenue/Share—
Last Price3.950 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS3724461047
Valuation
P/E (Trailing)0.12
P/E (Forward)-1.81
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.14
EPS (TTM)34.43
EPS (Forward)-2.18
52W Range
0.42296% of range55.00
52W High55.00 USD
52W Low0.4229 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-203.83%
ROA-159.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.31M $
CapEx (TTM)—
FCF Margin—
FCF Yield-333.84%
Net Debt-15.15M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.76
Quick Ratio6.47
Book Value/Sh29.23 USD
Cash/Share18.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:22
Split DateJul 16, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.819.71K
Float818.03K
Insiders0.21%
Institutions1.74%
Short Interest
Short Ratio1.1d
Short % Float7.32%
Short % Out.7.30%
Shares Short36.88K
Short (prev mo.)42.65K
Technical
SMA 508.720 (-54.7%)
SMA 20036.17 (-89.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)188.03K
Avg Vol (10d)564.46K
Technical Indicators
RSI (14)44.9
MACD0.0732
MACD Signal0.3802
MACD Hist.-0.3069
BB Upper8.278 USD
BB Middle5.378 USD
BB Lower2.477 USD
BB Width107.86%
ATR (14)0.6878 USD
Vol Ratio (20d)0.46x